Fu Shuang, Li Mengqi, Wang Hongtao
Department of Hematology Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
Front Pharmacol. 2023 Jun 16;14:1141311. doi: 10.3389/fphar.2023.1141311. eCollection 2023.
Acute promyelocytic leukemia (APL) is currently considered a disease with a higher cure rate. And cases of secondary malignant tumors following successful APL treatment are rare. Here we described a rare case of a 29-year-old man who was treated for APL in 2019 and developed -positive acute lymphoblastic leukemia 2 years later. The patient responded well to tyrosine kinase inhibitors and chemotherapy, and achieved a molecular remission. Although APL usually has a good prognosis, the prognosis of its secondary malignancies is uncertain. There are no effective measures to prevent the occurrence of secondary tumors. Continuing to increase the monitoring frequency of laboratory tests, especially the molecular biomarkers, is essential for the diagnosis and treatment of secondary malignancies after the patients achieving complete remission.
急性早幼粒细胞白血病（APL）目前被认为是一种治愈率较高的疾病。APL治疗成功后发生继发性恶性肿瘤的病例很少见。在此，我们描述了一例罕见病例，一名29岁男性在2019年接受了APL治疗，2年后发生了阳性急性淋巴细胞白血病。该患者对酪氨酸激酶抑制剂和化疗反应良好，并实现了分子缓解。虽然APL通常预后良好，但其继发性恶性肿瘤的预后尚不确定。目前尚无有效措施预防继发性肿瘤的发生。持续增加实验室检查的监测频率，尤其是分子生物标志物，对于患者完全缓解后继发性恶性肿瘤的诊断和治疗至关重要。
